BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20250101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260127
DTEND;VALUE=DATE:20260130
DTSTAMP:20260515T010905
CREATED:20251003T101634Z
LAST-MODIFIED:20251003T101634Z
UID:42113-1769472000-1769731199@www.pharmajournalist.com
SUMMARY:Non-Opioid Pain Therapeutics Summit
DESCRIPTION:The race to deliver safe\, effective non-opioid pain therapeutics has never been more urgent – or more achievable. After decades of setbacks\, the field is achieving long-awaited progress with recent regulatory approvals from Tonix and Vertex\, strategic acquisitions from Eli Lilly\, and late-stage successes validating the commercial potential of novel mechanisms. \nHowever\, the clinical pathway for pain remains one of the most challenging in drug development\, requiring smarter trial design\, validated endpoints\, patient stratification strategies\, and strong regulatory engagement. \nThe Inaugural Non-Opioid Pain Therapeutics Summit is the only meeting dedicated to overcoming the unique scientific and clinical barriers in pain drug development. Discussions will focus on optimizing trial design in chronic pain\, advancing mechanism-specific biomarkers\, addressing placebo response and patient stratification\, and aligning with regulators on validated endpoints. \nWith case studies spanning NaV inhibitors\, novel receptor targets\, and first-in-class modalities\, the summit provides the scientific depth and clinical perspective required to move non-opioid pain candidates successfully through the pipeline. \nAttendees will be learning from companies with approvals such as Tonix\, exploring late-stage strategies from innovators like Latigo and Algiax\, and uncovering discovery breakthroughs from Nocion and Axonis. Join 70+ discovery\, preclinical\, translational and clinical industry-based experts driving the future of non-opioid pain therapies across diverse pain indications. \nTo know more visit: https://ter.li/h7pe87
URL:http://www.pharmajournalist.com/event/non-opioid-pain-therapeutics-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260127
DTEND;VALUE=DATE:20260130
DTSTAMP:20260515T010905
CREATED:20251007T061903Z
LAST-MODIFIED:20251009T110319Z
UID:42127-1769472000-1769731199@www.pharmajournalist.com
SUMMARY:4th Ophthalmic Drug Delivery Summit
DESCRIPTION:With global cases of AMD\, DME\, and glaucoma rapidly increasing\, ophthalmic drug R&D is accelerating to meet urgent unmet needs. However\, poor treatment adherence\, invasive procedures\, and adverse side effects continue to limit therapeutic success\, highlighting the critical need for optimized delivery approaches. \nRecent developments\, including Genentech’s Susvimo label expansion\, advances in sustained-release and suprachoroidal delivery systems\, and Regeneron’s acquisition of Oxular\, demonstrate a growing industry focus on improving durability and reducing invasiveness. \nThat’s why 80+ industry leaders will gather at the 4th Ophthalmic Drug Delivery Summit this January to explore long-acting intravitreal and subretinal innovations\, emerging suprachoroidal techniques\, novel formulation strategies\, drug-device integration\, and evolving regulatory expectations. \nJoin experts across preclinical and clinical R&D\, formulation\, pharmacology\, devices\, and combination products for three days of focused discussions driving the future of safe\, effective\, and durable ophthalmic therapies. \nDownload the full event guide to find out all the topics to be discussed and the full expert speaker faculty: https://ter.li/vz7y60
URL:http://www.pharmajournalist.com/event/4th-ophthalmic-drug-delivery-summit/
LOCATION:Hilton San Francisco Financial District\, 750 Kearny St\, San Francisco\, CA\, 94108\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260127
DTEND;VALUE=DATE:20260130
DTSTAMP:20260515T010905
CREATED:20251104T084713Z
LAST-MODIFIED:20251104T100827Z
UID:42309-1769472000-1769731199@www.pharmajournalist.com
SUMMARY:7th RNAi-Based Therapeutics Summit
DESCRIPTION:2025 is proving to be a landmark year for RNAi. From Alnylam’s first approval in hemophilia to Novartis’ $1.2 billion acquisition of Avidity Biosciences and GSK diving into COPD with an $85 million siRNA licensing deal\, the headlines haven’t stopped. RNAi is officially outgrowing its liver roots and entering a new era of therapeutic expansion. \nWith so much momentum shaping the RNAi landscape\, there’s never been a more pivotal time for the community to come together. The 7th RNAi-Based Therapeutics Summit (January 27-29\, 2026 | Boston\, MA) is the industry-dedicated forum uniting the entire RNAi ecosystem from discovery and complex chemistry to clinical development and CMC. \nLearn more in the official event program here: https://ter.li/8c4zw3 \nThrough 30+ expert-led sessions\, explore how pioneers are moving beyond the liver to unlock new disease frontiers: \nExpanding Horizons to Systemic & Extrahepatic Diseases: \nReprogram metabolic health with dual-targeting siRNA for obesity and leverage multi-gene silencing miRNA to overcome chemo-resistance\, moving beyond appetite suppression and single-target inhibition for durable\, tissue-specific efficacy. \nBreaking Barriers in Brain & CNS Delivery: \nOvercome the blood-brain barrier with Trojan Horse formulations and intrathecal delivery to achieve significant protein knockdown in neurodegenerative diseases\, paving a clear path toward clinical development for severe neurological disorders. \nExamining Innovative Delivery Strategies for Enhanced Targeting: \nUtilize novel ligand platforms\, antibody conjugates\, and DNA origami nanostructures to achieve precise delivery to muscle\, kidney\, and adipose tissue\, optimizing cellular uptake and endosomal escape to avoid the limitations of conventional LNPs. \nEngineering Specificity & Safety Through Chemical Biology: \nApply advanced phosphorothioate patterns and 2′-modifications to transcend GalNAc\, actively directing biodistribution and improving therapeutic indices to build safer\, more precise RNAi drugs. \nOptimizing CMC & Formulation for Commercial Readiness:  \nAddress the unique synthesis\, characterization\, and manufacturing challenges of complex conjugates and novel chemistries to ensure quality\, stability\, and scalability for clinical and commercial supply. \nJoin discovery to clinical development teams from the top pharma and biotechs to de-risk your path to the clinic and accelerate your extrahepatic pipeline. \nWant to find more about registration options? Follow this link to go to the registration platform on our website: https://ter.li/n7bmw8
URL:http://www.pharmajournalist.com/event/7th-rnai-based-therapeutics-summit/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260127
DTEND;VALUE=DATE:20260130
DTSTAMP:20260515T010905
CREATED:20251111T142519Z
LAST-MODIFIED:20251111T142519Z
UID:42360-1769472000-1769731199@www.pharmajournalist.com
SUMMARY:4th Molecular Glue Drug Development Summit
DESCRIPTION:Molecular glues are leading the charge in the race to drug the previously undruggable\, and 2025 has seen continued investment and partnerships driving innovation in this field. Returning as the industry’s only dedicated meeting\, the 4th Molecular Glue Drug Development Summit brings top experts from biopharma and academia together for intimate networking and scientific content sharing. Designed to address the unique challenges of molecular glues\, this meeting will provide actionable strategies to accelerate the development of safer\, more selective candidates toward the clinic. \nAttendees will explore cutting-edge topics including target selection principles\, rational design frameworks\, sensitive assay technologies\, lead optimization\, and AI/ML approaches for rapid and reliable glue discovery. Delve into emerging frontiers in non-degrading molecular glues and approaches outside oncology to unlock new therapeutic modalities\, expand glues to novel indications\, and stay ahead of the curve in the glues space. \nIf you’re looking to lead the way in the molecular glue space\, connect with the brightest minds\, and gain practical insights to drive programs forward – this is your chance to solve the field’s unique challenges and shape the next wave of innovative therapies. \nExplore the 3 day event guide: https://ter.li/rhdyz0
URL:http://www.pharmajournalist.com/event/4th-molecular-glue-drug-development-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260127
DTEND;VALUE=DATE:20260130
DTSTAMP:20260515T010905
CREATED:20251111T143842Z
LAST-MODIFIED:20251111T143842Z
UID:42373-1769472000-1769731199@www.pharmajournalist.com
SUMMARY:5th mRNA-Based Therapeutics Summit Europe
DESCRIPTION:The 5th mRNA-Based Therapeutics Summit Europe is the leading European industry-focused forum dedicated to accelerating the safe\, scalable\, and clinically impactful development of messenger RNA (mRNA) medicines. Returning for its fifth year in Berlin from 27 – 29 January 2026\, this essential meeting unites 170+ senior leaders across R&D\, CMC (Chemistry\, Manufacturing\, and Controls)\, Regulatory Affairs\, Clinical Development\, and Business Strategy from Europe and around the globe. \nThe summit provides a comprehensive\, end-to-end program\, featuring never-before-seen preclinical and clinical data from industry trailblazers such as Moderna\, AstraZeneca\, and BioNTech. The agenda is meticulously structured to address the field’s most pressing challenges and opportunities: broadening mRNA’s scope beyond infectious disease vaccines into oncology\, rare diseases\, and beyond; overcoming the key bottleneck of targeted and tissue-specific delivery; and resolving complex CMC and stability hurdles for next-generation modalities like self-amplifying RNA (saRNA) and circular RNA (circRNA). \nNew for 2026 is a dedicated Gene Editing Focus Day\, highlighting how mRNA technology enables safer\, transient editing strategies and exploring its translational potential in regenerative indications. Attendees will gain actionable\, exclusive insights on critical topics including advanced LNP and polymeric delivery systems\, manufacturing scale-up\, and the integration of AI into mRNA design. \nAdditionally\, the summit offers high-profile investor sessions\, providing candid perspectives on the clinical milestones\, strategic proof points\, and investment signals necessary to make an mRNA platform fundable in today’s competitive landscape. By fostering collaboration and sharing best practices\, the 5th mRNA-Based Therapeutics Summit Europe is the premier platform to de-risk development pipelines and ensure the next generation of revolutionary mRNA medicines successfully reach patients. \nTo know more visit: https://ter.li/t3lsz2
URL:http://www.pharmajournalist.com/event/5th-mrna-based-therapeutics-summit-europe/
LOCATION:Hotel Palace Berlin\, Germany
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260127
DTEND;VALUE=DATE:20260130
DTSTAMP:20260515T010905
CREATED:20251204T125152Z
LAST-MODIFIED:20251204T125420Z
UID:42534-1769472000-1769731199@www.pharmajournalist.com
SUMMARY:6th Age-Related Disease Therapeutics Summit
DESCRIPTION:The 6th Age-Related Disease Therapeutics Summit is the leading global meeting dedicated to advancing therapies that target the biology of aging and age-related diseases. \nOver three days\, the summit brings together senior decision-makers from biopharma\, biotech innovators\, investors\, and academic researchers to accelerate the development and commercialization of next-generation therapeutics. \nAs the aging population grows\, the demand for interventions that extend healthspan and treat chronic conditions is at an all-time high. This meeting provides a unique platform for professionals to explore cutting-edge science\, clinical progress\, and translational strategies shaping this rapidly evolving field. \nFrom senolytics and cellular rejuvenation to mitochondrial health and systemic inflammation\, the summit covers the most promising approaches in age-related disease treatment. \nKey highlights include: \n\nDeep-dive sessions on therapeutic targets\, biomarker validation\, and regulatory pathways.\nInvestment & Funding Insights: Hear from leading investors and strategists on where capital is flowing in longevity and age-related disease innovation.\nNetworking Opportunities: Connect with C-suite executives\, R&D leaders\, and pioneering scientists driving breakthroughs in aging biology.\n\nHere are just some of the ground-breaking companies that will be presenting this year: \nAge 1 | BioAge Labs | Biolexis Therapeutics | Gordian Biotechnology | Insilico Medicine | Juvenescence | Kendall Capital Partners | Novartis | Rubedo Life Sciences | Telocyte \nFind out more\, here: https://ter.li/b3tokv
URL:http://www.pharmajournalist.com/event/6th-age-related-disease-therapeutics-summit-2026/
LOCATION:Hyatt Centric Fisherman’s Wharf\, 555 North Point Street\, San Francsico\, CA\, 94133\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260128
DTEND;VALUE=DATE:20260130
DTSTAMP:20260515T010905
CREATED:20251119T141849Z
LAST-MODIFIED:20251204T124644Z
UID:42408-1769558400-1769731199@www.pharmajournalist.com
SUMMARY:10th Tumor Models Summit San Francisco
DESCRIPTION:Join the West Coast’s premier pharma and biotech gathering\, the 10th Tumor Models Summit San Francisco\, where innovation meets opportunity in tumor modeling. \nAs the FDA phases out animal testing requirements and NIH redirects funding away from animal-only studies\, the oncology landscape is transforming. Exciting modalities like ADCs\, bispecifics\, T-cell engagers demand smarter\, more predictive models. CRISPR and AI are accelerating patient-derived model development at unprecedented speed. \nThis meeting unites industry leaders with cutting-edge vendors to navigate this pivotal shift. Network with pioneers shaping the future of optimizing model selection strategy\, discover breakthrough technologies\, and position your pipeline ahead of the curve. The industry is evolving; the time is now to be part of the conversation. \nDownload the full event guide to find out more: https://ter.li/phkowi
URL:http://www.pharmajournalist.com/event/10th-tumor-models-summit-san-francisco/
LOCATION:Hyatt Centric Fisherman’s Wharf\, 555 North Point St\, San Francisco\, 94133\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR